Nascent Biotech, Inc. (NBIO)
USD 0.06
(16.67%)
USD 0.06
(16.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 527.43 Thousand USD | 0.0% |
| 2023 | - USD | -255.25% |
| 2022 | -134.4 Thousand USD | 57.17% |
| 2021 | - USD | 58.8% |
| 2020 | -470.21 Thousand USD | -151.82% |
| 2019 | 41.00 USD | 38.38% |
| 2018 | 471.00 USD | -255.63% |
| 2017 | 1.43 Million USD | 126.22% |
| 2016 | - USD | -153.97% |
| 2015 | -2.14 Million USD | -275.88% |
| 2014 | -570.31 Thousand USD | 15.29% |
| 2013 | -625.1 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -516.03 Thousand USD | -40.65% |
| 2024 Q3 | -364.42 Thousand USD | 48.26% |
| 2024 Q1 | -511.95 Thousand USD | 100.0% |
| 2024 FY | - USD | -3.21% |
| 2024 Q2 | -837.08 Thousand USD | 0.0% |
| 2023 Q2 | -526.34 Thousand USD | 15.06% |
| 2023 Q1 | -619.67 Thousand USD | -33.27% |
| 2023 FY | - USD | -255.25% |
| 2023 Q4 | -539.7 Thousand USD | -13.65% |
| 2023 Q3 | -474.88 Thousand USD | 9.78% |
| 2022 Q2 | -265.23 Thousand USD | 47.89% |
| 2022 FY | - USD | 57.17% |
| 2022 Q1 | -508.95 Thousand USD | -287.46% |
| 2022 Q3 | 630.97 Thousand USD | 337.89% |
| 2022 Q4 | -464.97 Thousand USD | -173.69% |
| 2021 Q2 | -561 Thousand USD | -1.2% |
| 2021 Q1 | -554.34 Thousand USD | 81.2% |
| 2021 FY | - USD | 58.8% |
| 2021 Q4 | 271.49 Thousand USD | 146.31% |
| 2021 Q3 | -586.29 Thousand USD | -4.51% |
| 2020 FY | - USD | -151.82% |
| 2020 Q3 | -368.23 Thousand USD | -12.43% |
| 2020 Q2 | -327.52 Thousand USD | -19.65% |
| 2020 Q1 | -273.74 Thousand USD | 18.2% |
| 2020 Q4 | -2.94 Million USD | -700.59% |
| 2019 Q1 | -439.72 Thousand USD | 45.12% |
| 2019 Q4 | -334.63 Thousand USD | -30.43% |
| 2019 Q3 | -256.57 Thousand USD | 24.09% |
| 2019 FY | - USD | 38.38% |
| 2019 Q2 | -338.01 Thousand USD | 23.13% |
| 2018 Q1 | -298.89 Thousand USD | 35.64% |
| 2018 Q2 | -558.22 Thousand USD | -86.76% |
| 2018 Q3 | -563.62 Thousand USD | -0.97% |
| 2018 FY | - USD | -255.63% |
| 2018 Q4 | -801.29 Thousand USD | -42.17% |
| 2017 Q3 | -569.72 Thousand USD | -483.68% |
| 2017 FY | - USD | 126.22% |
| 2017 Q4 | -464.37 Thousand USD | 18.49% |
| 2017 Q2 | 148.49 Thousand USD | -46.62% |
| 2017 Q1 | 278.19 Thousand USD | 288.88% |
| 2016 Q1 | -36.21 Thousand USD | 96.04% |
| 2016 Q4 | -147.28 Thousand USD | -100.25% |
| 2016 Q3 | -73.54 Thousand USD | -104.74% |
| 2016 FY | - USD | -153.97% |
| 2016 Q2 | 1.55 Million USD | 4387.75% |
| 2015 Q2 | -322.76 Thousand USD | -27.55% |
| 2015 FY | - USD | -275.88% |
| 2015 Q1 | -253.05 Thousand USD | 31.86% |
| 2015 Q3 | -654.27 Thousand USD | -102.71% |
| 2015 Q4 | -913.56 Thousand USD | -39.63% |
| 2014 Q3 | -65.4 Thousand USD | 7.15% |
| 2014 Q2 | -70.44 Thousand USD | -5.5% |
| 2014 FY | - USD | 15.29% |
| 2014 Q4 | -371.36 Thousand USD | -467.81% |
| 2014 Q1 | -66.77 Thousand USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.742% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 108.896% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.822% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 103.036% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 99.439% |
| Mesoblast Limited | -62.38 Million USD | 100.845% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 134.337% |
| Genus plc | 73.7 Million USD | 99.284% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 107.977% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 114.87% |
| Marizyme, Inc. | -34.28 Million USD | 101.539% |
| ContraFect Corporation | -64.99 Million USD | 100.811% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 106.013% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 111.653% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 137.625% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 119.945% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 122.697% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 201.812% |
| Accustem Sciences Inc. | -3.74 Million USD | 114.078% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 101.094% |
| EV Biologics, Inc. | -1.26 Million USD | 141.624% |
| Q BioMed Inc. | -617.62 Thousand USD | 185.397% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 85.234% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 183.401% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 123.088% |
| Biomind Labs Inc. | -1.03 Million USD | 150.982% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 94.66% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 107.365% |
| Skye Bioscience, Inc. | -13.54 Million USD | 103.893% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 135.46% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2209.732% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 113.579% |
| IMV Inc. | -35.52 Million USD | 101.485% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 103.324% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 121.081% |
| GB Sciences, Inc. | -1.41 Million USD | 137.146% |
| Alpha Cognition Inc. | -9.7 Million USD | 105.434% |
| HST Global, Inc. | -5303.00 USD | 10045.936% |
| CSL Limited | 4.78 Billion USD | 99.989% |
| Halberd Corporation | -74.27 Thousand USD | 810.07% |
| Enzolytics Inc. | -2.12 Million USD | 124.855% |
| Resverlogix Corp. | -11.74 Million USD | 104.492% |
| Affymax, Inc. | -14.29 Million USD | 103.69% |
| SYBLEU INC | -141.57 Thousand USD | 472.557% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 117.219% |
| argenx SE | -216.02 Million USD | 100.244% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.953% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 56.661% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 135.188% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -39.222% |
| AVAX Technologies, Inc. | -6.11 Million USD | 108.629% |
| Zenith Capital Corp. | -8.6 Million USD | 106.129% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.212% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 3127.57% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 121.559% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 399.636% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 101.331% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 118.236% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 150.409% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -7744.036% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 130.139% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 127.457% |
| BioStem Technologies, Inc. | -7.55 Million USD | 106.982% |
| ONE Bio Corp. | 13.61 Million USD | 96.126% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 391.258% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 125.641% |
| Agentix Corp. | -1.37 Million USD | 138.449% |
| LadRx Corporation | 412.28 Thousand USD | -27.93% |
| Cell Source, Inc. | -4.27 Million USD | 112.345% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 243.628% |
| Regen BioPharma, Inc. | 1.46 Million USD | 64.021% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 156.293% |
| NovAccess Global Inc. | -1.03 Million USD | 150.97% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 94.043% |
| Itoco Inc. | -1.86 Million USD | 128.22% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 238.937% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 147.261% |
| Kadimastem Ltd | -2.62 Million USD | 120.097% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 320.545% |
| CytoDyn Inc. | -18.02 Million USD | 102.925% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 767.392% |
| Mobile Lads Corp. | -2.24 Million USD | 123.534% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 4412.969% |
| Qrons Inc. | -40.08 Thousand USD | 1415.918% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 208.597% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Rebus Holdings, Inc. | -951 Thousand USD | 155.461% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 149.664% |
| International Stem Cell Corporation | 202 Thousand USD | -161.105% |
| Bioxytran, Inc. | -3.82 Million USD | 113.807% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 1101.962% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 121.424% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 101.47% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 1272.073% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 119.263% |
| Neutra Corp. | -181.24 Thousand USD | 391.002% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 102.616% |
| PureTech Health plc | -11.62 Million USD | 104.536% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 102.617% |
| IXICO plc | -707 Thousand USD | 174.602% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 106.863% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 101.091% |
| CSL Limited | 4.73 Billion USD | 99.989% |
| Cellectis S.A. | -92.63 Million USD | 100.569% |